| Targeting KRAS in pancreatic cancer: new drugs on the horizon SF Bannoura, MH Uddin, M Nagasaka, F Fazili, MN Al-Hallak, PA Philip, ... Cancer and Metastasis Reviews, 1-17, 2021 | 92 | 2021 |
| KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? SF Bannoura, HY Khan, AS Azmi Frontiers in Oncology 12, 1013902, 2022 | 55 | 2022 |
| Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C–mutant cancers HY Khan, M Nagasaka, Y Li, A Aboukameel, MH Uddin, R Sexton, ... Cancer research communications 2 (5), 342-352, 2022 | 22 | 2022 |
| Connecting the human microbiome and pancreatic cancer RE Sexton, MH Uddin, S Bannoura, HY Khan, Y Mzannar, Y Li, ... Cancer and Metastasis Reviews 41 (2), 317-331, 2022 | 18 | 2022 |
| Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiation therapy HY Khan, M Kamgar, A Aboukameel, S Bannoura, BY Chung, Y Li, ... Advances in Radiation Oncology 8 (1), 101122, 2023 | 10 | 2023 |
| Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers HY Khan, M Nagasaka, A Aboukameel, O Alkhalili, MH Uddin, ... Molecular Cancer Therapeutics 22 (12), 1422-1433, 2023 | 8 | 2023 |
| Molecular analysis of XPO1 inhibitor and gemcitabine–nab‐paclitaxel combination in KPC pancreatic cancer mouse model MH Uddin, MN Al‐Hallak, HY Khan, A Aboukameel, Y Li, SF Bannoura, ... Clinical and Translational Medicine 13 (12), e1513, 2023 | 7 | 2023 |
| The clinical menin inhibitor ziftomenib and the nuclear export inhibitor selinexor synergistically inhibit the growth of MLL-r AML MH Uddin, A Aboukameel, H Khan, S Bannoura, A Deol, J Yang, G Dyson, ... Blood 142 (Supplement 1), 4168-4168, 2023 | 5 | 2023 |
| Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes B Warnecke, M Nagasaka, MNA Hallak J Clin Oncol 41 (16_suppl), 3128-3128, 2023 | 2 | 2023 |
| Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia S Dhiman, MH Uddin, V Dhillon, JJ Aguilar, A Aboukameel, H Khan, ... Blood 144 (Supplement 1), 2768-2768, 2024 | 1 | 2024 |
| Targeting guanine nucleotide exchange factors for novel cancer drug discovery SF Bannoura, HY Khan, MH Uddin, RM Mohammad, BC Pasche, AS Azmi Expert Opinion on Drug Discovery, 1-11, 2024 | 1 | 2024 |
| Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis SF Bannoura, A Aboukameel, HY Khan, MH Uddin, H Jang, E Beal, ... bioRxiv, 2023.12. 18.572102, 2023 | 1 | 2023 |
| A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma. M Kamgar, HY Khan, A Aboukameel, S Bannoura, BY Chung, A Szabo, ... Journal of Clinical Oncology 41 (4_suppl), TPS760-TPS760, 2023 | 1 | 2023 |
| Novel Combination of Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit MLL-r AML MH Uddin, A Aboukameel, H Khan, S Bannoura, Y Li, A Deol, J Yang, ... Blood 140 (Supplement 1), 8811-8812, 2022 | 1 | 2022 |
| XPO1 inhibition as a clinically viable strategy to enhance durability of response to KRASG12D inhibitor in pancreatic ductal adenocarcinoma. MN Al Hallak, HY Khan, A Aboukameel, S Bannoura, K Choucair, ... Journal of Clinical Oncology 43 (4_suppl), 736-736, 2025 | | 2025 |
| RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth SF Bannoura, A Aboukameel, HY Khan, MH Uddin, H Jang, EW Beal, ... Cancer letters 604, 217275, 2024 | | 2024 |
| 225P Nuclear exporter protein exportin 1 (XPO1) as a novel therapeutic target in pancreatic neuroendocrine tumors AS Azmi, MH Uddin, SF Bannoura, HM Khan, M Diab, S Kim, E Beal, ... Annals of Oncology 35, S97, 2024 | | 2024 |
| Tu1208 REGULATING THE REGULATOR: REGULATOR OF CHROMOSOME CONDENSATION 1 (RCC1) AS A NOVEL THERAPEUTIC TARGET FOR PANCREATIC DUCTAL ADENOCARCINOMA SF Bannoura, HY Khan, A Aboukameel, MH Uddin, R Nimri, S Kim, ... Gastroenterology 166 (5), S-1282, 2024 | | 2024 |
| Abstract CT080: A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic ductal adenocarcinoma M Kamgar, HY Khan, A Aboukameel, SF Bannoura, BY Chung, A Szabo, ... Cancer Research 84 (7_Supplement), CT080-CT080, 2024 | | 2024 |
| Regulator of chromosome condensation 1 (RCC1) as a novel therapeutic target in pancreatic ductal adenocarcinoma SF Bannoura, HY Khan, A Aboukameel, MH Uddin, R Nimri, E Beal, ... Cancer Research 84 (6_Supplement), 5587-5587, 2024 | | 2024 |
